贝达药业 (300558.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

73.1x

EV/EBITDA

22.9x

Market Cap

CNY 20.54B

MomentumView details →

1D Return

−5.18%

YTD Return

+4.90%

RSI (14)

39.1

ValuationView details →

P/E (Fwd)

73.1x

EV/EBITDA

22.9x

Market Cap

CNY 20.54B

RSI (14)

39.1

MomentumView details →

1D Return

−5.18%

YTD Return

+4.90%

ProfitabilityView details →

Gross Margin

78.98%

Net Margin

11.82%

EBITDA Margin

25.90%

ROE (TTM)

6.49%

ROA (TTM)

4.13%

Asset Turnover

0.35x

GrowthView details →

Revenue YoY

+21.40%

EPS YoY

+8.53%

FCF YoY

−60.14%

Revenue CAGR 3Y

+14.94%

EPS CAGR 3Y

+27.77%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.16

EPS Surprise

33.31%

Beats (12Q)

1/12

Next Q EPS Est

CNY 0.39

Avg Surprise (4Q)

33.31%

Rev Surprise

−9.02%

Capital & dividendView details →

Debt/Equity

0.25x

Current Ratio

0.99x

Quick Ratio

0.78x

Div Yield

0.31%

Div Rate

CNY 0.15

Div Growth 1Y

−24.60%

Financials snapshotView financials →

Revenue (TTM)

3.73B

Net Income (TTM)

441.16M

Op. CF (TTM)

877.33M

Next earningsOct 23, 2026 →

Latest newsMore news →

Betta Pharmaceuticals announced that China's National Medical Products Administration issued a drug registration certificate for ensartinib capsules (brand name: Benmeina), approving a new indication for adjuvant treatment of ALK-positive stage IB to IIIB non-small cell lung cancer after surgery, the third approved indication for ensartinib.2d ago

Betta Pharmaceuticals held a conference call on August 21, 2026 to discuss its 2026 half-year results, reporting revenue of 1.976 billion yuan, up 14% year-on-year.14d ago

Similar companies

汉缆股份002498.SZ 润丰股份301035.SZ 昊志机电300503.SZ 绿联科技301606.SZ 铖昌科技001270.SZ 科士达002518.SZ Find similar companies →

Latest newsMore news →

Betta Pharmaceuticals announced that China's National Medical Products Administration issued a drug registration certificate for ensartinib capsules (brand name: Benmeina), approving a new indication for adjuvant treatment of ALK-positive stage IB to IIIB non-small cell lung cancer after surgery, the third approved indication for ensartinib.2d ago Betta Pharmaceuticals held a conference call on August 21, 2026 to discuss its 2026 half-year results, reporting revenue of 1.976 billion yuan, up 14% year-on-year.14d ago